Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old~* Diagnosed with Schizophrenia or Schizoaffective disorder~* Ability to visit the doctor's office for scheduled visits~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* Have a body mass index (BMI) greater than 40~* Have diabetes, heart disease or any other unstable illness~* Have known positive human immunodeficiency virus (HIV)~* Are currently taking olanzapine, risperidone, clozapine, glucocorticoids, injectable antipsychotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): None
- Risperidone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).